Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2025
3,241
Period ended Dec 28, 2025
Change on a year earlier
-4.6%
3,396 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 3,241 | -4.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 3,396 | -23.1% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 4,418 | -18.9% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 5,449 | -6.5% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 5,825 | +64.4% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 3,543 | +3.8% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 3,413 | +3.3% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 3,304 | +4.8% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 3,154 | -1.7% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 3,208 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up infectious diseases (id) therapeutic area total — worldwide sales ($m)
- Infectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M)1,264 · FY2025
- Infectious Diseases (ID) Therapeutic Area Total — International sales ($M)1,977 · FY2025
- Infectious Diseases (ID) Therapeutic Area Total — Worldwide reported growth YoY (%)-4.6% · FY2025
- Infectious Diseases (ID) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)-6.5% · FY2025
- PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide sales ($M)1,579 · FY2025
- EDURANT / rilpivirine — Worldwide sales ($M)1,486 · FY2025
- COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M)198 · FY2024
- Other Infectious Diseases medicines — Worldwide sales ($M)175 · FY2025
Cite this data
StockData. (2026). Johnson & Johnson Infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_infectious_diseases
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.